Premium
A Long‐Term Study of the Efficacy of Oxandrolone in Hyperlipoproteinemias
Author(s) -
MALMENDIER CLAUDE L.,
BERGEN CLAUDINE J.,
EMPLIT GENEVIEVE,
DELCROIX CLAUDE
Publication year - 1978
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1978.tb01559.x
Subject(s) - oxandrolone , uric acid , triglyceride , medicine , endocrinology , cholesterol , chemistry , anabolic steroid , estrone , anabolism , hormone , growth hormone
Oxandrolone, an anabolic steroid, significantly reduced serum triglycerides in type III, IV, and V hyperlipoproteinemia, with a concomitant decrease in pre-beta lipoproteins. Its slightly enhancing effect on serum cholesterol and absolute increase in beta lipoproteins might eventually discourage its administration in type II patients. Alpha lipoproteins always remained at low levels. In addition to its hypotriglyceridemic action,, oxandrolone induced a slight reduction in uric acid and alkaline phosphatases. Untoward side effects were not observed even after prolonger therapy. Therefore, oxandrolone might deserve a place among the few available triglyceride-reducing therapies.